Our venture capital fund focuses investments on early-stage life sciences companies looking to improve people’s outcomes with cancer.

Recent News

C4-logo-wht
03/05/2024

C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024

READ MORE
C4-logo-wht
03/04/2024

C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

READ MORE
C4-logo-wht
02/22/2024

C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

READ MORE
wugen-logo-400
01/30/2024

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

READ MORE
aiProteins_Final_logo300
01/18/2024

Vivtex and AI Proteins Enter Strategic R&D Collaboration to Develop Novel, Oral Biologic Therapies for Inflammatory Diseases

READ MORE
Logo-Geneoscopy-400
01/17/2024

Geneoscopy Forms Scientific Advisory Board to Support Advancement of Precision Immunology Diagnostics for Inflammatory Bowel Disease (IBD)

READ MORE
Logo-Geneoscopy-400
01/12/2024

Geneoscopy Files Inter Partes Review Petition Challenging Exact Sciences’ Patent

READ MORE
C4-logo-wht
01/09/2024

C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines

READ MORE
C4-logo-wht
01/04/2024

C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals

READ MORE

PORTFOLIO HIGHLIGHTS

WUGEN Logo
White C4 Therapeutics logo
Geneoscopy logo
NextRNA Logo
CareVet Logo
microbial-logo-header300